The first is to select a good patient and grasp the “starting point” of treatment. Not all chronic hepatitis B patients need antiviral therapy, and not all chronic hepatitis B patients are suitable for antiviral therapy, this is very important. The second is to choose the right drug and implement standardized and individualized treatment. There are more and more drugs on the market that are claimed to be anti-hepatitis B virus, especially a large number of false advertisements and inaccurate propaganda, and it is important to go to a regular liver hospital for consultation. Third, take the inflection point and adjust the treatment strategy at the right time. Regardless of what program is chosen to start treatment, once implemented, attention should be paid to achieve timely monitoring. Fourth, be alert to drug resistance, early detection and early treatment. For example, the rate of drug-resistant variants is higher in patients treated with lamivudine and the timing may be earlier. In particular, patients with delayed HBVDNA decline during treatment tend to have earlier and more drug-resistant mutations, which should be closely observed. Fifth, adhere to treatment, with a full course of treatment, grasp the “end”. Clinical research and practice have shown that antiviral treatment for chronic hepatitis B requires long-term treatment in order to maximize the lasting inhibition of hepatitis B virus replication, thereby achieving the goal of controlling disease progression and preventing the development of cirrhosis and liver cancer. You must go to a qualified professional hospital to receive professional treatment from a specialist in a timely manner so as not to delay your condition.